Touchlight Genetics Ltd.

文章总览 2026年3月，多家IVD与生命科学公司发布新产品，覆盖基因分型、神经退行性疾病血液标志物、无细胞DNA合成、多重蛋白检测、细胞条码技术及AI平台等多个方向。技术路线集中在高通量多重检测（multiplexing）、血液标志物、无细胞合成与AI分析，反映出行业正在向多组学整合与高通量检测平台化发展。整体来看，新产品的共同目标是：提高检测通量、降低成本并增强临床可解释性。一、Agena：MassArray平台扩展CFTR突变检测能力 Agena Bioscience推出：iPlex Pro CFTR 100+ Panel（RUO） 核心特点： 覆盖100+ CFTR基因变异 包含ACMG 2023更新推荐的全部变异位点 基于MassArray（MALDI-TOF质谱）平台 技术优势： 单次反应实现多突变检测 适用于囊性纤维化（cystic fibrosis）及相关疾病研究 该产品本质上强化了质谱分型技术在遗传病检测中的多重能力。二、Siemens：血液pTau217检测切入神经退行性疾病 Siemens Healthineers发布脑健康研究产品组合，包括：Atellica IM pTau217检测Atellica IM Brain-Derived Tau（BDTau）检测 技术路线：血液化学发光免疫分析（chemiluminescent immunoassay） 在**Atellica系统（IM与CI分析仪）**上运行 检测内容：pTau217（关键阿尔茨海默病标志物）脑源性tau蛋白 应用方向： 神经退行性疾病早筛与分型 合作研究包括：PREDICTOMACCESS-ADBanner Sun Health Research Institute 趋势明确： 神经退行性疾病检测正在从CSF走向“血液标志物时代”三、NEB：推出无细胞dbDNA合成技术 **New England Biolabs（NEB）**与Touchlight合作推出：EnClose Cell-free dbDNA Synthesis Kit 核心技术：doggybone DNA（dbDNA） 一种线性、共价闭合的双链DNA 特点：无细胞合成（cell-free synthesis） 替代传统质粒DNA（plasmid DNA） 应用场景：核酸药物开发（DNA/RNA therapeutics）疫苗与基因治疗 该产品本质上解决了： DNA生产中的“细胞依赖”瓶颈四、Alamar：220蛋白神经多组学检测 Alamar Biosciences推出：NULISAseq Neuro 220 Panel 核心能力： 单样本检测220个蛋白标志物 升级点： 在原有120 panel基础上扩展 引入tau同种型（tau isoforms）检测 支持机构：Michael J. Fox Foundation 覆盖疾病： 阿尔茨海默病 帕金森病 多发性硬化 ALS 额颞叶痴呆 亨廷顿病等 趋势判断： 神经疾病进入“高维蛋白组标志物”竞争阶段五、Biotium：单管15重细胞条码分析 Biotium发布：ViaPlex 2-Color Cell Barcoding Kit 技术特点： 使用2种荧光染料（405 nm + 488 nm） 实现最多15个细胞群体标记（15-plex） 应用：流式细胞术（flow cytometry）多样本合并分析 价值在于： 降低样本处理成本 提高检测通量六、Mindera：AI驱动皮肤与免疫多组学平台 Mindera Health + Mountaineer Biosciences推出：Subtilitas平台 整合技术包括：无创皮肤采样分子多组学分析AI/机器学习 应用方向： 皮肤病 免疫相关疾病 目标用户：生物制药企业CRO学术研究机构 核心价值： 提升临床试验效率 支持个体化治疗七、NomosLogic：消费级+临床药物基因组平台 NomosLogic推出：Dendrite Lite（消费级）Clinical Standalone（临床版） 功能： 提供药物基因组学（pharmacogenomics）分析 特点： 支持导入：23andMeAncestryDNAMyHeritage 报告生成时间：约2分钟 价格：99 / 149 / 249美元 技术特点：可追溯、可审计（deterministic output） 趋势： PGx正在从临床走向消费级市场八、核心趋势总结 本批产品背后有三条非常清晰的行业主线： 1 高通量多重检测（High-plex） CFTR 100+ 220蛋白panel 15-plex细胞条码 2 血液与无创检测 pTau217 神经蛋白panel 3 平台化与AI驱动 Subtilitas 多组学+AI 以及一个值得注意的方向： 4 分子检测消费化 Dendrite Lite

IPSWICH, Mass., March 18, 2026 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight. This novel kit enables the benchtop enzymatic synthesis of Touchlight's proprietary doggybone ™ DNA (dbDNA), a linear, covalently closed, double-stranded DNA, providing researchers with a rapid, cell-free alternative to traditional plasmid DNA for the development of various nucleic acid therapeutics. "Traditional plasmid DNA manufacturing is a significant bottleneck in advanced therapies development, often requiring large-scale fermentation, cell banking, and long lead times that can slow the path to the clinic," said Dr. Ashley Luck, Associate Director of Applications and Development at NEB. "We're thrilled to offer a cell-free alternative that allows researchers to bypass these complex bacterial processes. This kit enables the rapid screening and production of high-purity DNA templates right at the benchtop, cutting months off the development timeline for mRNA vaccines and gene therapies." NEB built upon Touchlight's dbDNA technology by developing the EnClose Cell-free dbDNA Synthesis Kit, which offers a robust, optimized, and simplified enzymatic workflow, enabling scientists to generate high yields of closed-ended DNA in a single day. Unlike plasmid DNA, dbDNA is free of bacterial sequences and antibiotic resistance genes, minimizing safety concerns and simplifying regulatory compliance. The technology is linearly scalable from research to production, making it an ideal template for viral vector manufacturing — such as adeno-associated virus (AAV) and lentiviral (LV) vectors, non-viral gene therapy and a variety of nucleic acid therapeutics, including mRNA therapeutics and gene editing. Furthermore, the enzymatic process excels at synthesizing difficult sequences, such as long poly(A) tails and viral inverted terminal repeats, which are often unstable in bacterial cultures. "Collaborating with NEB allows us to significantly broaden the accessibility of our technology, directly into the hands of researchers for the first time," said Dr. Tommy Duncan, Chief Business Officer at Touchlight. "By combining our proprietary dbDNA technology with NEB's expertise in enzymology, we've optimized a workflow that allows scientists to screen constructs and prototype high-throughput designs rapidly, before moving on to larger-scale manufacturing." This dbDNA synthesis kit aligns with NEB's overarching commitment to support and streamline the development of RNA- and DNA- based therapies. By providing a direct entry into the nucleic acid therapeutic space with a scalable, cell-free template solution, NEB continues to expand its comprehensive portfolio of reagents and kits designed to support customers from discovery through to commercialization. More information on the EnClose Cell-free dbDNA Synthesis Kit can be found at NEB® and NEW ENGLAND BIOLABS® are registered trademarks of New England Biolabs, Inc. ENCLOSE™ is a trademark of New England Biolabs, Inc. DOGGYBONE™ and dbDNA™ are trademarks of Touchlight Genetics. About New England Biolabs: For over 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers' research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 10 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit . About Touchlight Touchlight is an innovation-driven leading CDMO pioneering enzymatic GMP DNA production to enable the genetic medicine revolution. As pioneers, with an FDA Drug Master File accepted in 2022 followed in 2025 with the world's first cell-free DNA GMP license, Touchlight's enzymatic DNA technology is on the cutting edge of AAV, mRNA, DNA vaccine, and gene editing technology with its state-of-the-art facility recognized by ISPE's Facility of the Year Awards (FOYA) for Innovation. With multiple client products already in the clinic, Touchlight's evidence-based, synthetic DNA manufacturing solutions offer a scalable, sustainable alternative to plasmid DNA (pDNA) for all stages of pre-clinical, clinical and commercial development. The company and technology are built on the conviction that DNA is fundamental to the future of medicine. Traditional methods, based on bacterial fermentation, are slow, costly, and unable to meet the growing demands of genetic medicine due to limited scalability and speed. Founded in 2007, Touchlight's team is inspired by breakthroughs in genetic medicine, recognizing the urgent need for innovative DNA production techniques to support the future of genetic therapies. For more information, visit SOURCE New England Biolabs, Inc. 21% more press release views with Request a Demo

10月6日，恰逢欧洲基因与细胞治疗学会年会（ESGCT）及西班牙基因与细胞治疗学会双年会前夕，科金生物两位科学创始人——Jose-Carlos Segovia教授（西班牙马德里 CIEMAT-CIBERER 研究所 / FIIS-FJD教授）以及Matthew Porteus教授（美国斯坦福大学教授，现任美国ASGCT主席）联合组织了一场以 “同源重组（HDR）：未来发展之路” 为主题的一日专题研讨会，并吸引了多国学者协助支持，David Rawlings, University of Washington, Seattle, USA; Paula Cannon, University of Southern California,g Los Angeles, USA; Ayal Hendel, Bar-Ilan University, Ramat-Gan, Israel; Justin Eyquem, University of California San Francisco, San Francisco, USA; Alessia Cavazza, University College London, London, UK; and Rasmus Bak, Aarhus University, Aarhus, Denmark等著名学者纷纷参会。此次研讨会在西班牙塞维利亚的ESGCT会场召开，得到了BE pharma, Synthego,阿斯利康，touchlight等公司的赞助支持。 On October 6th, just before the Annual Meeting of the European Society of Gene and Cell Therapy (ESGCT) and the Biennial Meeting of the Spanish Society of Gene and Cell Therapy, two scientific founders of DanausGT—Professor Jose-Carlos Segovia (from CIEMAT-CIBERER Institute / FIIS-FJD, Madrid, Spain) and Professor Matthew Porteus (from Stanford University, USA, and current President of the American Society of Gene and Cell Therapy, ASGCT)—jointly organized a one-day thematic symposium titled "Homologous Recombination (HDR): The Path Forward". The symposium garnered support from scholars worldwide, with renowned experts in attendance, including David Rawlings (University of Washington, Seattle, USA), Paula Cannon (University of Southern California, Los Angeles, USA), Ayal Hendel (Bar-Ilan University, Ramat-Gan, Israel), Justin Eyquem (University of California San Francisco, San Francisco, USA), Alessia Cavazza (University College London, London, UK), and Rasmus Bak (Aarhus University, Aarhus, Denmark). Held at the ESGCT venue in Seville, Spain, the symposium also received sponsorship and support from companies such as BE pharma, Synthego, AstraZeneca, and Touchlight. 会议详情，点击链接即可查看：https://www.luminaeu.com/hdr-2025  同源重组（HDR）技术目前是编辑人类基因组运用最广泛的方式之一，本次研讨会聚焦 HDR 技术优化与临床应用，为深入探讨如何在所有核酸酶平台上推进并优化 HDR 技术奠定基础，更为 HDR 领域的学术交流与技术合作搭建了重要平台，进一步推动了该技术在临床转化中的发展，为基因编辑治疗相关疾病提供了更多可能。最新临床进展，更证明了科金生物已经在HDR基因精准插入技术的临床应用上走到了世界前沿。 Matthew Porteus教授会上分享 Professor Matthew Porteus shares research progress 会上，Segovia教授代表科金生物公布了自主研发的完整基因替换技术平台针对丙酮酸激酶缺乏症的临床试验DNGT001，全球首例患者的最新临床数据。经过长达一年的随访，获得了良好的安全数据。截至目前，全球有三例患者接受了HDR基因治疗（在不同适应症），科金生物作为全球首个丙酮酸激酶缺乏症临床实验者，用数据奠定了领域先驱者的地位。 On the symposium, on behalf of DanausGT Biotech, Professor Segovia announced the latest clinical data of DNGT001 , a clinical trial for Pyruvate Kinase Deficiency (PKD) based on the company's independently developed full gene replacement technology platform, involving world's first patient. After a one-year follow-up, favorable safety data were obtained. Up to now, three patients worldwide have received HDR gene therapy for different indications. As the global pioneer in conducting clinical trials for PKD, DanausGT Biotech has established its position as a forerunner in the field with solid data. Jose-Carlos Segovia教授分享最新进展和临床数据 Professor Segovia shares research progress and latest clinical data 科金生物基因替换技术平台可在敲除致病基因的基础上，利用同源重组原理，同时实现在原位精准的Knock in插入正常基因来恢复和增强基因功能。这种一石二鸟的技术在很多疾病领域有独特的优势，突破常规疗法单一性的限制，可同时做到消除病灶和恢复增强，使诸多常规疗法无法治好或者治疗效果不好的疾病有了更好的选择，应用范畴遍及遗传病、癌症、认知障碍症，乃至抗衰老，是基因治疗的理想目标，代表了基因治疗的发展方向。 DanausGT's gene replacement technology platform can, on the basis of knocking out pathogenic genes, utilize the principle of homologous recombination to simultaneously achieve precise in-situ Knock-in of normal genes, thereby restoring and enhancing gene function. This two-in-one technology has unique advantages in many disease areas: it breaks the limitation of the singularity of conventional therapies, can simultaneously eliminate lesions and restore/enhance gene function, and provides a better option for many diseases that are incurable or poorly treated by conventional therapies. Its application scope covers genetic diseases, cancer, cognitive disorders, and even anti-aging. It represents the ideal goal and development direction of gene therapy. 丙酮酸激酶缺乏症（PKD）： 丙酮酸激酶缺乏症是一种罕见的常染色体隐性遗传疾病。可导致患者出现慢性溶血性贫血，即红细胞加速破坏。PKLR基因的突变会导致红细胞能量的缺失，其主要表现为PK酶活性降低、ATP生成减少及上游代谢产物的积聚，造成红细胞能量缺失，并加速红细胞的死亡产生溶血性贫血，甚至导致死亡。 Pyruvate Kinase Deficiency (PKD) is a rare autosomal recessive genetic disorder. It can lead to chronic hemolytic anemia in patients, which accelerates the destruction of red blood cells. Mutations in the PKLR gene can lead to a loss of red blood cell energy, mainly manifested as decreased PK enzyme activity, reduced ATP production, and accumulation of upstream metabolites, resulting in red blood cell energy loss and accelerating red blood cell death, leading to hemolytic anemia and even death. Abouts 关 于 科 金 生 物 无锡科金生物科技有限公司（简称：科金生物）成立于 2022 年 1 月，母公司位于江苏无锡，并在西班牙、香港和上海成立研发中心。团队成员都来自诺华，罗氏，药明康德等世界知名药企，并有诺奖团队成员以及两名国家人才带队。 公司专注于细胞与基因治疗，自主研发的完整基因替换技术平台可以精准地插入或者替换基因，从基因层面根治疾病。这种一石二鸟的技术在很多疾病领域有独特的优势，突破常规疗法单一性的限制，可同时做到消除病灶和恢复增强，范畴遍及遗传病、癌症、认知障碍症，乃至抗衰老。 除了疾病领域的应用，基因精准插入，还可以让个体安全的增加新的功能，未来在农业林业，甚至国防领域都会有应用。这是一项充满想象力的技术，期待人们的生活会因为我们的技术变得更加美好。 NEWS 新闻资讯 首批入驻上海生物医药前沿产业创新中心，科金生物乘风起航 孤儿药 | EMA授予科金生物治疗Wisckott-Aldrich氏症候群的孤儿药资格认定 全球首例！上海儿童医学中心联手科金生物完成首例PKD患儿基因替换治疗，临床研究初显成效 让治愈成为标准 让老百姓用得起基因治疗 点分享 点点赞 点在看